A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Remodulin Warnings, Precautions, Pregnancy, Nursing, Abuse - Treprostinil sodium
Remodulin Warnings, Precautions, Pregnancy, Nursing, Abuse - Treprostinil sodium
WARNINGS
Remodulin is indicated for subcutaneous use only.
PRECAUTIONS
General
Remodulin should be used only by clinicians experienced in
the diagnosis and treatment of PAH.
Remodulin is a potent pulmonary and systemic vasodilator. Initiation
of Remodulin must be performed in a setting with adequate personnel and equipment
for physiological monitoring and emergency care. Subcutaneous therapy with Remodulin
may be used for prolonged periods, and the patient’s ability to administer Remodulin
and care for an infusion system should be carefully considered.
Dose should be increased for lack of improvement in, or worsening
of, symptoms and it should be decreased for excessive pharmacological effects
or for unacceptable infusion site symptoms (see DOSAGE
AND ADMINISTRATION).
Abrupt withdrawal or sudden large reductions in dosage of Remodulin
may result in worsening of PAH symptoms and should be avoided.
Information for Patients
Patients receiving Remodulin should be given the following
information: Remodulin is infused continuously through a subcutaneous catheter,
via an infusion pump. Therapy with Remodulin will be needed for prolonged periods,
possibly years, and the patient's ability to accept, place, and care for a subcutaneous
catheter and to use an infusion pump should be carefully considered. Additionally,
patients should be aware that subsequent disease management may require the
initiation of an intravenous therapy.
top
